Mankind Pharma Q4: Profits Rise By 52% YoY To Rs 294 Cr

Mankind Pharma, the Indian pharma major announced its financial results for the fourth quarter and full year ended March 31, 2023. The company's Profit After Tax (PAT) in the fourth quarter surged by 52 per cent year on year (YoY) to Rs 294 crore against Rs 193 crore recorded in the corresponding quarter last year. In FY23 the company's profit dipped by 10 per cent YoY to Rs 1,310 crores compared with 1,453 crores in FY22. 

Mankind's revenue from operations increased by 12 per cent YoY to Rs 8,749 crore in FY23 compared with Rs 7,782 crore in FY22. Whereas in Q4FY23 the pharma company posted a revenue of Rs 2,053 crores against Rs 1,726 crores in the same quarter of the previous year. 

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) registered a 45 per cent rise YoY in the March quarter to be recorded at Rs 419 crores and for FY23 the company reported EBITDA at Rs 1,913 crores, down by 5 per cent over FY22.

Mankind's EBITDA margins improved in Q4FY23 to 20.4 per cent versus 16.8 per cent in Q4FY22. For FY23 the margins dropped to 21.9 per cent versus 25.8 per cent in FY22.